2020 Kentucky Harm Reduction Summit

Trauma-Informed Approaches, Harm Reduction, and Minimizing Potential Harms of Our Services

Activity Details
  • Credit Amounts:
    • CME: 0.75
    • Other: 0.75
    • CNE: 0.75
  • Cost: Free
  • Release: Mar 5, 2024
  • Expires: Mar 4, 2027
  • Estimated Time to Complete:
    45 Minutes
  • Average User Rating:
    ( Ratings)
This content was recorded from the live internet event on August 19th and 20th, 2020. If you attended and claimed credit, please do not complete this release. 

Faculty

Laura Pegram Laura Pegram, MSW, MPH
Associate Director, Drug User Health Team
National Alliance of State and Territorial AIDS Directors (NASTAD)
Washington, DC

Needs Statement

Often services for People Who Use Drugs (PWUDs) are created in ways that can be coercive and not Trauma-Informed. This session looks at alignment between TIA and Harm Reduction services and philosophy to improve our services and work with PWUDs and improve health outcomes.

Target Audience

This activity is designed for physicians, nurse practitioners, nurses, physician assistants, first responders, public health professionals and students, and other interested healthcare or public health professionals.

Objectives

At the end of this session, participants should be able to:

  • Discuss harm reduction as a trauma-informed approach related to HIV prevention/care and drug user health and social/environmental factors that might increase likelihood of trauma
  • Describe methods to mitigate trauma within services
  • Improve service delivery and reach PWUDs more effectively, particularly regarding the role of trauma, intergenerational trauma, vicarious trauma, and mental health

Accreditation

Joint Accreditation LogoIn support of improving patient care, this activity has been planned and implemented by University of Kentucky HealthCare CECentral and the Kentucky Department of Public Health. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA credit: 
This enduring material is designated for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC credit:
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 nursing contact hour(s).

Other credit:
UK Healthcare CECentral certifies this activity for 0.75 hours of participation.

Faculty Disclosure

No speakers, planners, or reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

This activity is jointly provided by the University of Kentucky and Kentucky Department of Public Health.

In collaboration with the Lake Cumberland District Health Department (LKDHD), Kentucky Injury Prevention and Research Center University of Kentucky College of Public Health (KIPRC), Kentucky Department for Public Health (KDPH), Kentucky Income Reinvestment Program (KIRP), Kentucky AIDS Education Training Center (KYAETC), and the Department for Behavioral Health, Developmental and Intellectual Disabilities (DBHDID)